VivoSeq
Oncology

Adenoid Cystic Carcinoma

41

Pipeline Programs↗

12

Active Trials↗

24

Companies Involved↗

Adenoid Cystic Carcinoma is a moderately active landscape with 41 programs across 24 companies. The most active players are Rgenta Therapeutics Inc, Imclone, Merck & Co.. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

15/100

Mech. Concentration

11/100

Completion Rate

87/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Rgenta Therapeutics Inc

1 program

Phase 1I

Imclone

1 program

Phase 1Merck & Co. logo

Merck & Co.

2 programs

Phase 2E

Elevar Therapeutics

1 program

Phase 2R

Remix Therapeutics

1 program

Phase 2A

Ayala Pharmaceuticals, Inc,

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

33 of 41 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody615%Antibody–drug conjugate12%Protein / enzyme12%

Small molecule leads; the ring shows all 41 classified programs, each share of the total. Modality classified for 100% of 42 pipeline programs.

Analysis

Trial Status

42

clinical trials

Completed20 · 48%
Unknown status7 · 17%
Recruiting7 · 17%
Active, not recruiting3 · 7%
Terminated3 · 7%
Not yet recruiting2 · 5%

Clinical Trials

Trial Activity

42 trials

Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma
Recruiting·QQingdao Central Hospital·Phase 2·NCT04974866·20 enrolled
A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06891560·34 enrolled
Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma
Recruiting·HHitGen Inc.·Phase 2·NCT06781567·140 enrolled
Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study
Recruiting·EEye & ENT Hospital of Fudan University·Phase 2·NCT07320508·100 enrolled
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
Recruiting·RRgenta Therapeutics Inc·Phase 1·NCT06462183·105 enrolled
A Phase 1/2 Study of CB-103 (Oral Pan-NOTCH Inhibitor) With Abemaciclib or Lenvatinib in Combination in Patients With NOTCH Activated Adenoid Cystic Carcinoma (CALCulus)
Recruiting·—·Preclinical·NCT05774899·32 enrolled
A Phase 1/2, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
Recruiting·RRemix Therapeutics·Preclinical·NCT06118086·125 enrolled
Amivantamab in Adenoid Cystic Carcinoma
Active, not recruiting·—·Phase 2·NCT05074940·18 enrolled
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04209660·64 enrolled
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02780310·33 enrolled
Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)
Not yet recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07162480·28 enrolled
ZANACC: Phase 2 Non-randomized Single Arm Study Evaluating Zanzalintinib in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck
Not yet recruiting·UUNICANCER·Phase 2·NCT07682675·51 enrolled
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02098538·38 enrolled
An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma
Completed·MMayo Clinic·Phase 2·NCT06521775·6 enrolled
Study of RAD001 in Adenoid Cystic Carcinoma
Completed·SSeoul National University Hospital·Phase 2·NCT01152840·33 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)